|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 CHF | +9.07% |
|
-3.55% | -10.12% |
| Apr. 26 | Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment | MT |
| Apr. 11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
Idorsia Ltd reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported revenue was CHF 130.87 million compared to CHF 43.29 million a year ago. Net loss was CHF 181.25 million compared to CHF 635.08 million a year ago.
Basic loss per share from continuing operations was CHF 1.02 compared to CHF 3.58 a year ago. Diluted loss per share from continuing operations was CHF 1.02 compared to CHF 3.58 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.12% | 371M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
IDORSIA LTD 
